• Praxis Precision Medicines recently secured two major US FDA milestones, including Priority Review for relutrigine in pediatric epilepsy (PDUFA in September 2026) and acceptance of the NDA for ulixacaltamide in essential tremor (PDUFA in January 2027), supported by earlier positive data such as a 71% patient response rate to elsunersen.
• This rare convergence of late-stage neurology catalysts highlights how Praxis’s precision neuroscience platform is maturing into a multi-asset regulatory pipeline rather than a single-drug story.
• With FDA Priority Review now in hand for relutrigine, we’ll examine how this accelerates and reshapes Praxis Precision Medicines’ existing investment narrative.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis, you have to believe its precision neuroscience approach can translate late stage epilepsy and movement disorder assets into approved therapies despite ongoing losses and dilution risk. The new FDA Priority Review for relutrigine and NDA acceptance for ulixacaltamide sharpen the near term focus on successful approvals, but do not change that the biggest current risk remains clinical or regulatory setbacks across this small cluster of key programs.

Among the recent milestones, the FDA’s Priority Review for relutrigine in SCN2A and SCN8A developmental epileptic encephalopathies is most relevant here, because it converts an early stage epilepsy narrative into a concrete, time bound decision point in September 2026. How that review progresses will help investors gauge whether Praxis can truly become a multi asset neurology company rather than relying on a single epilepsy franchise.

Yet even with these regulatory tailwinds, investors should be aware that...

Praxis Precision Medicines' narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and a $362.5 million earnings increase from $-273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue near US$2.1 billion and earnings around US$784 million by 2029, and with four late stage CNS assets plus five readouts on the table, those projections reflect a far more aggressive view than the baseline narrative you saw earlier, reminding you that opinions on Praxis’s upside and risk can differ widely and may shift again as the new relutrigine and ulixacaltamide decisions approach.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth less than half the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• Find 53 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.